Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores

NCT03192306 | Completed Phase 2 Results FDA Drug

• 1 other identifier: TR-H-212
• Study Type: interventional
• Target: 451
• Locations: 1 country
• Sites: 6

Brief Summary

The purpose of this study is to determine if Merlin, a mixture of ethanol and glycolic acid, is safe and effective in the treatment of cold sores. Subjects who meet the requirements to participate in the study will be put randomly, and equally, into one of two groups: 1) a group receiving Merlin to treat their cold sore; or 2)a group receiving a placebo of just ethanol to treat their cold sore. Neither the subject nor the site will know which treatment they will be getting. Once the subject has been assigned to a treatment group, they will be given a kit containing a bottle of the treatment and special swabs to apply the liquid. The subject will be told to take the kit home and wait until they think they are starting to get a cold sore. Once a subject begins to see something that they think is the start of a cold sore, they are to immediately call the clinic. Once the clinic confirms that the subject is in fact starting to get a cold sore, the subject will be told to open the kit and begin treatment. From the start of treatment, there will be twelve (12) treatments, with either Merlin or placebo, applied six (6) hours apart, up to 3 per day, over the next 96 hours (4 days). Each treatment of Merlin or placebo is made up of three (3) applications given twenty (20) minutes apart, for a total of thirty-six (36) applications. For each application, the subject will use the special swab to put the Merlin or placebo solution on their cold sore. Subjects will need to report daily to the clinic for a minimum of 3 consecutive days, until either the cold sore is completely healed or 14 days from the start of treatment, whichever comes first. At each clinic visit the cold sore will be observed to determine at what stage it is at or if it has healed. The subject will also be asked how they are feeling. Subjects will also be told to record in a diary the time of each application of Merlin or placebo. They will also be asked to record the stage of their lesion and how much pain, if any, related to the cold sore, that they are feeling.

Conditions

Recurrent Herpes Labialis

Keywords

Herpes Labialis; Cold Sore

Outcome Measures

Primary Outcomes (1)

• Clinician Assessed Duration of the Classical Herpetic Lesion

  The time in hours from beginning of treatment to onset of Stage 6 (residual swelling) or Stage 7 (complete healing) if Stage 6 never observed

  From time of beginning of treatment until onset of Lesion Stage 6 or Stage 7, if Stage 6 never observed, with a maximum of 14 days.

Secondary Outcomes (6)

• Clinician Assessed Duration of the Herpetic Episode

  For classical lesions: from the beginning of the treatment until loss of hard crust (Stage 6); for non-classical lesions the time from the beginning of treatment until complete resolution of all local signs and symptoms (Stage 7) - maximum of 14 days

• Clinician Assessed Duration Until Complete Healing of the Herpetic Episode

  From the beginning of treatment to onset of Stage 7 - maximum of 14 days

• Clinician Assessed Prevention of Progression to Classical Lesion

  14 days maximum

• Clinician Assessed Lesion Size

  14 days maximum

• Clinician Assessed Duration of the Herpetic Lesion Hard Scab

  From start of Stage 5 to loss of hard crust - maximum of 14 days

Study Arms (2)

Merlin

ACTIVE COMPARATOR

glycolic acid and ethanol mixture

Drug: Merlin

Ethanol

PLACEBO COMPARATOR

Drug: Ethanol

Interventions

Merlin DRUG

glycolic acid/ethanol solution

Merlin

Ethanol DRUG

Ethanol solution

Ethanol

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subject 18-75 years of age
• Female subjects must be using a medically acceptable form of birth control during the study. Acceptable birth control measures include, but are not limited to: abstinence, oral contraceptive pills or patch, injectable contraception, barrier contraceptives (condom, diaphragm with spermicide), IUD, vaginal contraceptive ring, surgical (hysterectomy, tubal ligation), vasectomized partner, and natural post-menopausal inability to conceive. Menopause is defined for this protocol as starting one year after the time of the last menstrual period.
• Subject must have a history of recurrent herpes labialis and report at least 3 separate recurrences (i.e. multiple herpetic lesions in one outbreak count as only one episode) during the preceding 12 months.
• Subject must have a history of experiencing prodromal symptoms of cold sores (e.g. itching, tingling, or burning) during at least half of their previous cold sore episodes.
• Subject must have a history of at least half of their cold sore episodes producing classical lesions (i.e., episodes that progressed through macule, papule, vesicle, crust, and healed).
• Subject must provide voluntary written informed consent to participate in this study.
• Subject is able to appear for a clinic visit within 24 hours from the time of treating cold sore and is able to return to the clinic for the full 14 day duration of the study if necessary.

You may not qualify if:

• Subjects with evidence of active malignancy or immunodeficiency disease within the last 30 days. Subjects who have completed therapy and are considered unlikely to relapse or who have had surgery and do not have any evidence of disease, are eligible for the study.
• Subject requires chronic use of immunomodifying drugs (e.g. systemic steroids) or topical steroids on or near the face; use of inhaled steroids does not exclude a subject from the study. If a subject is unlikely to get through the Treatment Phase of the protocol without requiring the use of an immunomodifying drug for a chronic condition the subject should be excluded.
• Subject requires chronic use of anti-viral medication. In females of childbearing potential, a positive urine pregnancy test at time of screening.
• Nursing mothers.
• Subject has abnormal skin conditions (e.g. acne, eczema, rosacea, psoriasis, albinism, or chronic vesiculobullous disorders) that occur in the area ordinarily affected by cold sores or has significant facial hair in the area of the cold sore that might affect the normal course of the cold sore or might impair accurate evaluation of the cold sore lesion.
• Subject has had a vaccine for herpes simplex virus type 1 (typically oral herpes) or 2 (typically genital herpes).
• Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device.
• Subject requires chronic use of analgesics or non-steroidal anti-inflammatory agents (NSAIDs) except for low doses of aspirin (less than 325 mg/day) used for cardiovascular purposes. If a subject is unlikely to get through the Treatment Phase of the protocol without requiring the use of analgesia for a chronic condition, e.g. back pain, recurrent daily headaches, the subject should be excluded.

Sponsors & Collaborators

• Topical Remedy: lead
• Benu BioPharma, LLC: collaborator
• Accelovance: collaborator
• Optimal Research: collaborator

Study Sites (6)

Optimal Research

Huntsville, Alabama, 35802, United States

Location

Optimal Research

San Diego, California, 92108, United States

Location

Optimal Research

Melbourne, Florida, 32934, United States

Location

Optimal Research

Peoria, Illinois, 61614, United States

Location

Optimal Research

Rockville, Maryland, 20850, United States

Location

Optimal Research

Austin, Texas, 78705, United States

Location

MeSH Terms

Conditions

Herpes Labialis

Interventions

Neurofibromin 2; Ethanol

Condition Hierarchy (Ancestors)

Herpes Simplex; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Lip Diseases; Mouth Diseases; Stomatognathic Diseases; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Membrane Proteins; Proteins; Amino Acids, Peptides, and Proteins; Tumor Suppressor Proteins; Neoplasm Proteins; Alcohols; Organic Chemicals

Results Point of Contact

• Title: Dr. Eric Morrel, VP Clinical Research
• Organization: Benu BioPharma, Inc.

emorrel@benubio.com

5082085634

Study Officials

• Stephen A Bart, Sr., M.D.

  Optimal Research Rockville MD

  PRINCIPAL INVESTIGATOR

• Murray A Kimmel, DO

  Optimal Research Melbourne FL

  PRINCIPAL INVESTIGATOR

• Daniel H Brune, MD

  Optimal Research Peoria IL

  PRINCIPAL INVESTIGATOR

• Stephen Daniels, DO

  Optimal Research Austin TX

  PRINCIPAL INVESTIGATOR

• Randle T Middleton, MD

  Optimal Research Huntsville AL

  PRINCIPAL INVESTIGATOR

• Patrick Yassini, MD

  Optimal Research San Diego CA

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 13, 2017
• First Posted: June 20, 2017
• Study Start: July 5, 2017
• Primary Completion: December 11, 2017
• Study Completion: April 2, 2018
• Last Updated: September 12, 2018
• Results First Posted: August 16, 2018

Record last verified: 2018-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (6)